Cipla announces USFDA inspection update for Medispray facility

Cipla (BSE: 500087) announced today an update regarding the United States Food and Drug Administration (USFDA) inspection of its Medispray Laboratories Private Limited facility in Kundaim, Goa. The inspection, which took place between January 14th and 20th, 2025, has resulted in the USFDA classifying the inspection as Voluntary Action Indicated (VAI). The notification was received via email communication on April 11th, 2025. Cipla has stated that the information disclosed is not material and is being made as part of good governance practice. The announcement was made on April 17th, 2025, within 24 hours of receiving the communication.